预约演示
更新于：2024-12-31
Cyproheptadine Hydrochloride
盐酸赛庚啶
更新于：2024-12-31
概要
基本信息
非在研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C42H50Cl2N2O3 |
InChIKeyZEAUHIZSRUAMQG-UHFFFAOYSA-N |
CAS号41354-29-4 |
关联
25
项与 盐酸赛庚啶 相关的临床试验NCT06751290
The Use of Cyproheptadine to Improve Eating Habits in Children With Pediatric Feeding Disorders
IRCT20240213060992N1
Comparing the effect of low dose and standard dose Cyproheptadine on BMI enhancement in children aged 2-10 and evaluation of its side effects
NCT06147622
A Phase 1, Open-label, Cross-over Study in Healthy Volunteers to Assess the Pharmacokinetic Profile of Prazosin and Cyproheptadine Following Single Dose Oral Administration of KT110 Tablet and Following Administration of Alpress and Periactin Marketed Tablets
100 项与 盐酸赛庚啶 相关的临床结果
登录后查看更多信息
100 项与 盐酸赛庚啶 相关的转化医学
登录后查看更多信息
100 项与 盐酸赛庚啶 相关的专利（医药）
登录后查看更多信息
291
项与 盐酸赛庚啶 相关的文献（医药）2024-12-01BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
Cyproheptadine is preferable to benzodiazepines in mild cases of serotonin syndrome (toxicity)
Article
作者: Mullins, Michael E.
2024-12-01MOLECULAR BIOLOGY REPORTS
Cyproheptadine inhibits in vitro and in vivo lung metastasis and drives metabolic rewiring
Article
作者: Sarwar, Md Shahid ; Pan, Yuxin ; Xu, Jiawei ; Peter, Rebecca Mary ; Shannar, Ahmad ; Rossi, Fabio ; Chou, PoChung Jordan ; Kong, Ah-Ng ; Dave, Parv Dushyant
Abstract:
Background:
Non-small cell lung cancer (NSCLC) accounts for 81% of lung cancer cases, among which over 47% presented with distant metastasis at the time of diagnosis. Despite the introduction of targeted therapy and immunotherapy, enhancing the survival rate and overcoming the development of resistance remain a big challenge. Thus, it is crucial to find potential new therapeutics and targets that can mitigate lung metastasis and investigate its effects on biomarkers, such as cellular metabolomics. In the current study, we investigated the role of cyproheptadine (CPH), an FDA-approved anti-histamine drug in lung metastasis in vitro and in vivo.
Methods and results:
CPH showed potent cytotoxicity on different lung cancer cell lines in vitro. Moreover, CPH decreased invasion and migration of LLC1 and A549 cells in Matrigel invasion transwell and plate scratch assays. The in vivo LLC1 syngeneic lung cancer model found decreased number of metastatic nodules on the surface of lungs of Setd7 KO mice compared to SETD7 WT. CPH treatment resulted in decreased growth of LLC1 subcutaneous tumors compared to untreated SETD7 WT. Finally, metabolomic study of tumor tissues showed rewiring of metabolomic pathways and downregulation of amino acids, such as arginine, serine, and glycine) in Setd7 KO and WT treated with CPH compared to untreated Setd7 WT mice.
Conclusion:
These findings identify CPH as a potential therapeutic agent to block metastasis in advanced NSCLC and suggest SETD7 as a potential target for the prevention of lung metastasis.
2024-11-01JOURNAL OF CLINICAL INVESTIGATION
Postprandial metabolomics analysis reveals disordered serotonin metabolism in post-bariatric hypoglycemia
Article
作者: Ozturk, Berkcan ; Saeed, Hamayle ; Efthymiou, Vissarion ; Wang, Hanna ; Cummings, Cameron J. ; Mulla, Christopher M. ; Casanova Querol, Pilar ; Simonson, Donald C. ; Poulos, Lindsay ; Simonson, Donald C ; Ferraz-Bannitz, Rafael ; Patti, Mary-Elizabeth ; Mulla, Christopher M ; Sandoval, Darleen A ; Pan, Hui ; Sandoval, Darleen A. ; Wang, Hanna J. ; Dreyfuss, Jonathan M. ; Dreyfuss, Jonathan M ; Navarrete, Valerie ; Cummings, Cameron
BACKGROUNDBariatric surgery is a potent therapeutic approach for obesity and type 2 diabetes but can be complicated by post-bariatric hypoglycemia (PBH). PBH typically occurs 1-3 hours after meals, in association with exaggerated postprandial levels of incretins and insulin.METHODSTo identify mediators of disordered metabolism in PBH, we analyzed the plasma metabolome in the fasting state and 30 and 120 minutes after mixed meal in 3 groups: PBH (n = 13), asymptomatic post-Roux-en-Y gastric bypass (post-RYGB) (n = 10), and nonsurgical controls (n = 8).RESULTSIn the fasting state, multiple tricarboxylic acid cycle intermediates and the ketone β-hydroxybutyrate were increased by 30%-80% in PBH versus asymptomatic. Conversely, multiple amino acids (branched-chain amino acids, tryptophan) and polyunsaturated lipids were reduced by 20%-50% in PBH versus asymptomatic. Tryptophan-related metabolites, including kynurenate, xanthurenate, and serotonin, were reduced 2- to 10-fold in PBH in the fasting state. Postprandially, plasma serotonin was uniquely increased 1.9-fold in PBH versus asymptomatic post-RYGB. In mice, serotonin administration lowered glucose and increased plasma insulin and GLP-1. Moreover, serotonin-induced hypoglycemia in mice was blocked by the nonspecific serotonin receptor antagonist cyproheptadine and the specific serotonin receptor 2 antagonist ketanserin.CONCLUSIONTogether these data suggest that increased postprandial serotonin may contribute to the pathophysiology of PBH and provide a potential therapeutic target.FUNDINGNational Institutes of Health (NIH) grant R01-DK121995, NIH grant P30-DK036836 (Diabetes Research Center grant, Joslin Diabetes Center), and Fundação de Amparo à Pesquisa do Estado de São Paulo grant 2018/22111-2.
100 项与 盐酸赛庚啶 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 湿疹 | 中国 | 1982-01-01 | |
| 食欲减退 | 日本 | 1971-01-01 | |
| 结膜炎 | 美国 | 1961-10-17 | |
| 常年性变应性鼻炎 | 美国 | 1961-10-17 | |
| 瘙痒 | 日本 | 1961-08-11 | |
| 过敏性鼻炎 | 日本 | 1961-08-11 | |
| 荨麻疹 | 日本 | 1961-08-11 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 22 | (Arm I Cyproheptadine Hydrochloride) | 構夢網鬱遞願鑰簾範醖(獵鏇繭膚遞齋繭築鏇憲) = 積願積願艱壓壓醖網糧 簾窪鏇顧夢遞鏇製網憲 (觸齋艱餘鹹觸壓窪襯窪, 夢構網鹽構鏇構窪艱範 ~ 蓋願簾選鏇積選鏇觸願) 更多 | - | 2015-07-02 | ||
placebo (Arm II Placebo) | 構夢網鬱遞願鑰簾範醖(獵鏇繭膚遞齋繭築鏇憲) = 夢齋觸選鹹鹽願醖簾繭 簾窪鏇顧夢遞鏇製網憲 (觸齋艱餘鹹觸壓窪襯窪, 鹽鑰繭網憲鏇窪醖網鹽 ~ 顧鹽鏇鹽淵齋淵齋鏇衊) 更多 | ||||||
N/A | - | 蓋蓋簾蓋構夢顧糧製廠(醖艱窪顧鹹製壓構壓夢) = 鹽壓網鏇糧夢鹹憲鬱鹹 鏇鑰廠廠鏇範構壓壓鬱 (廠範積選選夢築糧鬱鬱, 1.2) | - | 2010-11-17 | |||
Placebo | 蓋蓋簾蓋構夢顧糧製廠(醖艱窪顧鹹製壓構壓夢) = 顧鏇齋遞衊鹽獵鏇積鬱 鏇鑰廠廠鏇範構壓壓鬱 (廠範積選選夢築糧鬱鬱, 1.2) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用